Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWei LiuYWYi Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved outcomes with autologous stem cell transplantation in relapsed/refractory large B-cell lymphoma, highlighting promising progression-free survival.

Key Points

  • Combined therapy achieved an overall response rate of 93.3% among 15 patients with R/R LBCL, revealing strong efficacy.
  • After median follow-up duration of 25.1 months, two-year progression-free survival rate was 65.2%, indicating long-lasting effects.
  • Patients faced manageable cytokine release syndrome and neurotoxicity, demonstrating acceptable safety profile.
  • Autologous stem cell transplantation may enhance CAR T-cell therapy outcomes, suggesting a viable treatment strategy for eligible patients.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df56https://doi.org/10.1182/blood-2025-3720
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  2. 2Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience2025
  3. 3Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.2026
  4. 4CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  5. 5Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma2025 · 20 citations